Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11)
Yunpeng Yang, Hui Zhou, Li Zhang
Topics & Concepts
MedicinePembrolizumabPemetrexedClinical endpointLung cancerInternal medicineOncologyRegimenPopulationClinical trialFamily medicineCancerChemotherapyImmunotherapyEnvironmental healthCisplatinCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsPancreatic and Hepatic Oncology Research